title: Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis.
abstract: BACKGROUND
  Cardiac surgery is occasionally complicated by massive blood loss that is refractory to standard hemostatic interventions. Recombinant factor VIIa (rF-VIIa) is being increasingly used as rescue therapy in such cases, but little information is available on its safety and efficacy for this indication.
  
  
  METHODS
  The outcomes of the first 51 cardiac surgery patients who received rF-VIIa for intractable blood loss (from November 2002 to February 2004) at a single institution according to a standardized clinical guideline were compared to 51 matched control patients, with the control patients identified from a large database and matched based on the propensity for massive blood loss.
  
  
  RESULTS
  Blood loss and blood product usage were significantly decreased after 2.4 to 4.8 mg of rF-VIIa. In those treated after sternal closure (n = 32), there was a significant reduction in blood loss from the hour before to the hour after treatment: 100 (70, 285) mL (median [25th, 75th percentiles]; p < 0.0001). Except for a slower postoperative recovery and higher incidence of acute renal dysfunction, the adverse event rates were similar between the rF-VIIa-treated patients and their matched controls.
  
  
  CONCLUSIONS
  These results suggest that rF-VIIa may be an effective rescue therapy for patients with intractable hemorrhage after cardiac surgery. A clinically important risk of stroke or other major thrombotic complications could not be ruled out by our study. Controlled clinical trials with adequate power to detect the impact of rF-VIIa therapy on morbidity and mortality therefore are necessary before one can recommend its routine use in patients undergoing cardiac surgery who have excessive bleeding.
authors.affiliation: Department of Anesthesia, University of Toronto, University Health Network, Toronto, Ontario, Canada. keyvan.Karkouti@ohu.on.ca
authors.forename: Keyvan
authors.initials: K
authors.lastname: Karkouti
authors.forename: W Scott
authors.initials: WS
authors.lastname: Beattie
authors.forename: D N
authors.initials: DN
authors.lastname: Wijeysundera
authors.forename: Terrence M
authors.initials: TM
authors.lastname: Yau
authors.forename: Stuart A
authors.initials: SA
authors.lastname: McCluskey
authors.forename: Mohammed
authors.initials: M
authors.lastname: Ghannam
authors.forename: David
authors.initials: D
authors.lastname: Sutton
authors.forename: Adriaan
authors.initials: A
authors.lastname: van Rensburg
authors.forename: Jacek
authors.initials: J
authors.lastname: Karski
mesh_terms: D001777:Blood Coagulation / Q000187:drug effects; D006348:Cardiac Surgical Procedures / Q000009:adverse effects*; D016022:Case-Control Studies; D002423:Cause of Death; D015942:Factor VIIa / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019106:Postoperative Hemorrhage / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D015942:Factor VIIa